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Zinc as an adjunct therapy in the management 
of severe pneumonia among Gambian children: 
randomized controlled trial
Background The benefit of zinc as an adjunct therapy for severe 
pneumonia is not established. We assessed the benefit of adjunct 
zinc therapy for severe pneumonia in children and determined 
whether the study children were zinc deficient.
Methods This was a randomized, parallel group, double-blind, 
placebo-controlled trial with an allocation ratio of 1:1 conducted 
in children with severe pneumonia to evaluate the efficacy of dai-
ly zinc as an adjunct treatment in preventing ‘treatment failure’ 
(presence of any sign of severe pneumonia) on day-5 and day-10 
and in reducing the time to resolution of signs of severe pneumo-
nia. Six hundred and four children 2-59 months of age present-
ing with severe pneumonia at six urban and rural health care fa-
cilities in The Gambia were individually randomised to receive 
placebo (n = 301) or zinc (n = 303) for seven days. To determine 
if the study children were zinc deficient, supplementation was 
continued in a randomly selected subgroup of 121 children from 
each arm for six months post-enrolment, and height-gain, nutri-
tional status, plasma zinc concentrations, and immune compe-
tence were compared.
Results Percentage of treatment failure were similar in placebo 
and zinc arms both on day 5 (14.0% vs 14.1%) and day 10 (5.2% 
vs 5.9%). The time to recovery from lower chest wall indrawing 
and sternal retraction was longer in the placebo compared to zinc 
arm (24.4 vs 23.0 hours; P = 0.011 and 18.7 vs 11.0 hours; 
P = 0.006 respectively). The time to resolution for all respiratory 
symptoms of severity was not significantly different between pla-
cebo and zinc arms (42.3 vs 30.9 hours respectively; P = 0.242). 
In the six months follow-up sub-group, there was no significant 
difference in height gain, height-for-age and weight-for-height 
Z-scores, mid upper arm circumference, plasma zinc concentra-
tions, and anergy at six months post-enrolment.
Conclusions In this population, zinc given as an adjunct treat-
ment for severe pneumonia showed no benefit in treatment fail-
ure rates, or clinically important benefit in time to recovery from 
respiratory symptoms and showed marginal benefit in rapidity of 
resolution of some signs of severity. This finding does not support 
routine use of zinc as an adjunct treatment in severe pneumonia 
in generally zinc replete children.
Trial registration ISRCTN33548493.
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Pneumonia is the leading cause of death in children worldwide, accounting for 17% of almost 6 million 
deaths in children under 5 years of age in 2015, most of these occurring in sub-Saharan Africa [1,2]. In 
Gambia, pneumonia is a leading cause of death in young children [3,4].
To achieve the Global Action Plan for the Prevention and Control of Pneumonia (GAPPD) goal of reduc-
ing mortality from pneumonia in children under 5 years of age to fewer than 3 per 1000 live births by 
2025 innovative and effective interventions are required [5]. One such potential intervention is therapeu-
tic zinc.
Zinc deficiency impairs growth and may contribute to child death due to pneumonia. However, the ben-
eficial impact of zinc supplementation on respiratory infection is not clear. A meta-analysis of preventive 
zinc supplementation trials showed a significant reduction in the incidence and prevalence of pneumonia 
among children of 2 to 59 months of age in Bangladesh, India, Peru, and South Africa [6]. However, a 
meta-analysis of trials of therapeutic zinc supplementation as an adjunct to antibiotic for treatment of se-
vere and non-severe pneumonia in Bangladesh, Nepal and India did not show any benefit [7], although 
an earlier study in Bangladesh [8] showed beneficial impact.
Zinc deficiency is associated with diets high in phytate and fibre and low in protein. Because most of the 
dietary energy intake in Gambian children is derived from cereals and ground nuts, and intake of animal 
products is extremely low, the Gambian diet places children at risk of zinc deficiency [9]. The best meth-
od of confirming zinc deficiency in a population is to show a positive response to supplementation through 
well-designed randomized controlled trials [10]. Therefore, we conducted this trial to assess the benefit 
of short-term adjunct zinc therapy for severe pneumonia in children and also to determine whether the 
study children had clinically measureable zinc deficiency by assessing the impact of continued long term 
supplementation of zinc on growth and immune competence after recovery from severe pneumonia.
METHODS
Study setting
The Gambia is a small West African country of 1.8 million population with an HIV infection prevalence 
of less than 2% [11]. A randomized, parallel group, double-blind, placebo-controlled trial with an allo-
cation ratio of 1:1 was conducted in children with severe pneumonia to evaluate the efficacy of daily zinc 
as an adjunct treatment in preventing ‘treatment failure’ and reducing the time to resolution of signs of 
severe pneumonia. The trial was undertaken at a peri-urban (the Greater Banjul area) and a rural (the 
Upper River Region) setting (Figure 1). Participants were recruited from the MRC hospital, EFST Hos-
pital, Basse District Hospital, and the major health centres at Fajikunda, Serekunda, and Brikama.
Figure 1. Map of Gambia showing study sites: Greater Banjul area (periurban site) and Upper 
River Region (rural site).
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Procedures
Randomisation and blinding
An independent statistician allocated treatment in 604 children to one of the two arms by individual ran-
domisation. Unique identification numbers of study children were randomly allocated to placebo or zinc 
using block randomisation (block size = 10). Separate randomisation lists were generated for each health 
facility, with separate lists for children aged 2-12 months and 12-59 months, using Stata version 12.0. A 
randomly selected list of 242 children (121 in each arm) was generated at the outset for the subset of 
children enrolled for the study of 6 months zinc supplementation post-enrolment. The randomisation 
lists with allocation were kept by the Data Safety Monitoring Board. The study code was broken after all 
data were entered and initial blinded analysis had been performed.
Each tablet contained placebo or 10 mg elemental zinc as zinc sulphate (NUTRISET-B.P. 35-76770, Ma-
launay, France). The tablets were water-dispersible, identical in appearance, smell and taste, and were 
supplied in blister packs of 7 or 14 tablets. The blister packs were identical in appearance except for the 
batch numbers (which identified whether the pack contained placebo or zinc) and the expiry date print-
ed at the edge. Individual randomisation packs numbered to correspond to the randomisation lists were 
prepared and the printing at the edge of the blister pack was cut off to ensure blinding.
We decided to give fixed doses of 10 mg elemental zinc daily for infants and 20 mg daily for children be-
tween 12 and 59 months of age as the vast majority of published zinc supplementation trials have used 
these doses without any adverse effect. In this trial zinc was administered for 7 days, as the response to 
zinc repletion is extremely rapid because of small body zinc pool and in an earlier trial beneficial impact 
on recovery from severe pneumonia was observed within 7 days [8]. For the subgroup of 242 children 
included for the six month follow-up study, supplementation was continued with the same dosage for a 
total of 6 months post-enrolment.
Enrolment
All children who presented with a history of cough or difficulty in breathing at the outpatient departments 
were screened by nurses for eligibility. Substantial training of study nurses on WHO criteria for classifi-
cation and management of children with cough or difficulty in breathing was conducted and quality con-
trol of counting of respiratory rates and recognition of severe pneumonia instituted. Cases were children 
aged 2-59 months with severe pneumonia defined clinically by modified WHO criteria [12] (cough or 
difficulty in breathing plus any of the following: lower chest wall indrawing (LCWI), nasal flaring, or an 
oxygen saturation of <90% on pulse oximetry, the latter defining very severe pneumonia). Children with 
a cough of ≥2 weeks duration, with known congenital or metabolic abnormality, convulsion or uncon-
sciousness, severe malnutrition (defined as weight-for-height z-score<-3 or oedema of both feet (WHO) 
[12], clinically suspected systemic infection other than pneumonia, confirmed wheeze at recruitment, 
severe anaemia (PCV<18%, or Hb <6 g/dL), or living outside the study area were excluded from the study.
A study paediatrician confirmed eligibility. The parents or the main caregivers were informed about the 
details of the trial, invited to allow their child to participate, and written informed consent obtained. The 
child was randomised to a treatment arm by the study paediatrician using the randomisation lists. Clin-
ical findings were recorded on pre-tested standardised clinical record forms.
Administration of zinc and placebo
Placebo or zinc was administered by study nurses within one hour of administration of antibiotics. Sub-
sequent doses were administered once daily before the first morning feed. Each child received supple-
mentation for 7 days. A randomly selected subgroup of 242 children continued receiving study medica-
tion at home weekly for six months in total. During the weekly visits the health worker collected the 
previous supplement packaging and recorded the amount of left over tablets. A standard multivitamin 
supplement was given to all children during hospitalisation while no additional mineral supplements 
were given.
Anthropometry
WHO guidelines were followed for measuring weight and length [13]. Clinical staff and field workers 
were trained and standardised in the measurement of weight and height before starting the trial and the 
process of standardisation was repeated periodically throughout the trial. Length/height was measured 
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using length boards/stadiometers (ShorrBoardR, Maryland, USA) with a precision of 0.1 cm and weight 
was measured using electronic weighing scales (Digital Baby Scale, Model 727, Seca, Hamburg, Germa-
ny) with a precision of 10 grams. Weight was measured daily during hospitalisation.
Inpatient clinical care
All participants were given standardised clinical care as inpatients based on WHO guidelines [12] and 
standard operating procedures. This included antibiotic therapy for severe pneumonia and all supportive 
care. Those with severe pneumonia were reviewed a minimum of once daily by a medical doctor and 6 
hourly by a nurse; for those with very severe pneumonia a minimum of twice daily medical review and 
3 hourly nursing review was undertaken. Oxygen saturation was measured using standard commercially 
available pulse oximeters. For patients receiving oxygen, the oxygen cannula was withdrawn for five min-
utes and respiratory rate and signs of severe pneumonia and oxygen saturation were measured. Axillary 
temperature was measured using a digital thermometer. The study paediatricians confirmed treatment 
failure (defined below) and antibiotic therapy was changed according to WHO guidelines. All cases of 
treatment failure were closely observed until resolution of the signs. Children were discharged when all 
of the following conditions were met for a minimum of 24 consecutive hours: signs of severe or very se-
vere pneumonia were no longer present; fast breathing had resolved; axillary temperature <37.5°C; and 
no other contraindication to discharge was present.
Children discharged before day-5 were visited by a health worker at day-5 and day-10, and children dis-
charged between day-5 and day-10 were visited on day-10.
Laboratory tests
Two thick blood films for malaria were examined at day-0 and on any day during follow-up in the sub-
group with 6 months follow-up if there was a temperature of >37.5°C. On enrolment full blood count 
and blood cultures were performed. A chest x-ray was performed on all participants as soon as possible 
after enrolment.
Plasma zinc, ferritin, and soluble transferrin receptor (sTfR) were measured for the sub-group of children 
at enrolment and at 6 months post-enrolment at the MRC Human Nutrition Centre in Cambridge. Zinc 
was measured on Siemens Dimension Xpand using a reagent kit manufactured by Audit Diagnostics (Car-
rigtwohill, Co. Cork, Republic of Ireland). Ferritin was measured on Siemens Dimension Xpand using 
Siemens reagent FERR. sTfR was measured by ELISA using the Ramco kit, semiautomated on the BEST 
sample processor (Launch Diagnostics). All assays were conducted in accordance with standard operat-
ing procedures and ISO 9001:2008, including quality control samples alongside study samples and sub-
scribing to national external quality assessment schemes where available. Samples for these tests were 
collected using trace element free needle, syringe and tubes. Soluble transferrin receptor - ferritin (sTfR-F) 
index was calculated as the ratio of sTfR to log ferritin values. The sTfR-F index gives an estimate of total 
body iron and is considered a more reliable index than plasma ferritin and other conventional laboratory 
iron parameters in diagnosing iron deficiently anaemia (IDA) and, in non-inflamed individuals, is also as 
reliable as bone marrow aspirate in detecting iron stores in patients with IDA [14].
Cell-mediated immunity (CMI) skin test
A CMI skin test was conducted at 6 months post-enrolment in the sub-group receiving six months zinc 
supplementation. The kit (Merieux Multitest, Insitut Merieux, Lyon, France) comprised a sterile dispos-
able plastic multipuncture applicator with eight heads preloaded with standardized doses of seven anti-
gens (Tetanus, Diphtheria, Streptococcus, tuberculosis, Candida, Trychophyton, and Proteus) in glycerine 
solution and a glycerine-negative control that were applied to the volar surface of the right arm of each 
child. The diameter of each area of induration was measured by specially-trained nurses 48 hours after 
administration using the pen method [15]. A reaction was considered positive if the average of the max-
imum horizontal and vertical induration was at least 2 mm.
Sample size
The original sample size calculation for the impact of zinc supplementation on severe pneumonia out-
come was based on data from an RCT conducted in a non-stunted but generally zinc-deficient population 
in Bangladesh [8]. In this study failure rates of 3% in the supplemented group and 11% in the unsupple-
mented group were observed in children without wheezing. We expected failure rates to be 30% lower 
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in non-stunted Gambian children than Bangladeshi children (i.e 7.5% in the placebo group and 1.8% in 
the zinc group). Based on this assumption and allowing for 20% dropout, we aimed to recruit 300 chil-
dren per arm to have 80% power to detect a difference between the arms at an alpha level of 0.05.
The sample size for length gain following zinc supplementation for 6 months post-discharge was based 
on Ethiopian data [16] in stunted children where the length gain after 6 months was 7.0 cm (SD±7.37) 
in the zinc-supplemented group and 2.8 cm (SD±6.03) in the placebo group. We anticipated a length 
gain of 5.5 cm in the supplemented group and 2.8 cm in the placebo group and similar standard devia-
tions. Allowing for 20% dropout, we therefore aimed to recruit 120 in each arm to have 80% power to 
detect a difference between the study arms at an alpha level of 0.05.
Data analysis
Baseline characteristics of the placebo and zinc arms were compared to check for any imbalance in prog-
nostic factors. We undertook intention-to-treat analysis.
Short term endpoints
The primary endpoint of the trial was treatment failure on day-5 and day-10. Treatment failure was de-
fined as the presence of cough or difficulty in breathing with at least one of the following signs: LCWI or 
nasal flaring or hypoxaemia (oxygen saturation <90%). The secondary outcomes were time to resolution 
of hypoxaemia, LCWI, nasal flaring, grunting, head nodding, sternal retraction, central cyanosis, 
fast-breathing (≥50 per min in children 2-11 months and ≥40 per min in children 12-59 months), all 
three main signs of severity (LCWI, nasal flaring, hypoxaemia), and time to discharge.
The proportion of children who failed to respond to treatment by day-5 was measured for the placebo 
and zinc groups. Children who died before day-5 were also classed as treatment failures, while children 
who were discharged before day-5 and lost to follow up (ie, not seen by a health worker at day-5) were 
excluded from the analysis. A logistic regression model was used to adjust for baseline imbalance in age, 
sex, height-for-age (HAZ) and weight-for-height (WHZ) Z-scores, and pneumonia severity. The HAZ and 
WHZ were calculated using the WHO standards as the reference distribution [17]. Treatment failure at 
day-10 was analysed similarly.
The Kaplan-Meier method was used to estimate the median time to resolution for each of the symptoms 
of severe and very severe pneumonia (hypoxaemia, LCWI, nasal flaring, grunting, sternal retraction, head 
nodding, central cyanosis, and fast-breathing) among those individuals who had the symptoms at base-
line. In addition it was used to estimate the median time to the resolution of all signs of severity. For each 
symptom, we compared the placebo and zinc groups by fitting a Weibull accelerated failure time (AFT) 
model to the data. The regression parameter from this model - the ratio of median resolution times was 
used to quantify the effect of treatment on time to resolution and adjusted estimates were obtained by in-
cluding the covariates listed above for the primary outcome in the model. For all time to event analyses 
(ie, Kaplan-Meier estimates and AFT models) children were censored at date of death, date of discharge 
or day-10 if the symptom(s) had not resolved at this point.
Long term endpoints
Rates of growth from enrolment to six months later were estimated separately for each child using ordi-
nary least squares regression. Average rates of growth were presented separately by trial arm and the crude 
difference calculated. Linear regression was used to estimate the difference in growth rate (cm per month) 
between the trial arms adjusted for baseline age, sex, WHZ, HAZ, pneumonia severity, and zinc concen-
tration.
Additionally we compared between trial arms mean height, HAZ, WHZ, plasma zinc, ferritin, sTfR con-
centrations, and sTfR-F index, CRP, the proportion of children who were anergic, and the proportion 
malnourished (using Mid Upper Arm Circumference) . Linear regression was used to estimate adjusted 
differences, except for anergy and malnutrition where crude odds ratios were used to compare trial arms 
since these were recorded as binary variables and there were too few children with these outcomes to use 
regression models. The linear regression models included covariates as listed above for the analysis of 
growth rate.
Changes in plasma zinc, ferritin, sTfR, sTfR-F, and CRP concentrations between baseline and six months 
were tested using Wilcoxon matched-pairs signed-ranks test.
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Ethics approval
The study was approved by the Gambian Government-Medical Research Council Joint Ethics Committee 
(SCC/EC1062). The trial was registered in the ISRCTN registry at www.isrctn.com as ISRCTN33548493, 
and run according to Good Clinical Practice guidelines.
RESULTS
We recruited children between 28 November 2005 and 31 January 2011; follow up ended on 11 July 2011. 
10840 children were screened for eligibility, of which 604 were eligible and enrolled in the trial (Figure 
2). 121 children in each arm were allocated for 6 months continued zinc supplementation for assessing 
the long-term impact of daily zinc supplementation in this population with 98 children in the placebo arm 
and 100 children in the zinc arm available for analysis at the end of the 6 months (Figure 3).
The characteristics of children at enrolment were similar in placebo and zinc arms (Table 1). Median age 
at enrolment in both arms was 13.0 months. 7.0% in the placebo and 4.0% in the zinc arm were severe-
ly stunted, and 8.4% in the placebo and 6.6% in the zinc arm were severely wasted, and 14.0% in the 
placebo arm and 12.2% in the zinc arm had hypoxaemia.
There was no significant difference in the proportion of treatment failure on day-5 (14.0% vs 14.1%) or 
on day-10 (5.2% vs 5.9%) in placebo and zinc arm respectively (Table 2). The time to recovery from 
LCWI and sternal retraction was longer in the placebo compared to zinc arm (24.4 vs 23.0 hours; P = 0.011 
and 18.7 vs 11.0 hours; P = 0.006 respectively). There was no significant difference in time to recovery 
for other symptoms measured.
In the 6-month zinc supplementation sub-group there was no significant difference in the rate of height 
gain, HAZ, WHZ, mid upper arm circumference, anergy, and concentrations of plasma zinc, ferritin, sTfR, 
CRP, and in sTfR-F index (Table 3). Compared to baseline concentrations: median zinc concentration 
increased significantly and median ferritin concentration decreased significantly in both arms after six 
months; median sTfR concentration did not change in placebo arm but increased significantly in the zinc 
arm, and median sTfR-F index increased significantly in both arms (Figure 4).
Figure 2. Profile of entry of patients into the trial (short term).
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Table 1. Baseline characteristics of children with severe pneumonia enrolled in the trial
CharaCteristiCs PlaCebo ZinC
Gender Male 165 (54.8) 163 (53.8)
Female 136 (45.2) 140 (46.2)
Age (months) 2-5 56 (18.6) 66 (21.8)
6-11 76 (25.2) 66 (21.8)
12-23 93 (30.9) 100 (33.0)
24-35 51 (16.9) 54 (17.8)
36-59 25 (8.3) 16 (5.3)
60+ 0 (0.0) 1 (0.3)
Median (IQR) 13.0 (7.0, 24.0) 13.0 (6.0, 23.0)
Height-for-age z-score ≤-3.00 21 (7.0) 12 (4.0)
-2.99 to -2.00 25 (8.4) 28 (9.3)
-1.99 to -1.00 68 (22.8) 69 (22.8)
>-1.00 184 (61.7) 193 (63.9)
Median (IQR) -0.7 (-1.6, 0.1) -0.6 (-1.4, 0.3)
Weight-for-height Z-score ≤-3.00 25 (8.4) 20 (6.6)
-2.99 to -2.00 75 (25.2) 52 (17.2)
-1.99 to -1.00 97 (32.6) 110 (36.4)
>-1.00 101 (33.9) 120 (39.7)
Median (IQR) -1.4 (-2.3,-0.8) -1.3 (-2.0, -0.6)
Oxygen saturation (%) ≤89 42 (14.0) 37 (12.2)
90-93 54 (18.1) 58 (19.1)
≥100 203 (67.9) 208 (68.6)
Median (IQR) 95.0 (93.0, 97.0) 95.0 (92.0, 97.0)
Respiratory rate 35-39 2 (0.7) 1 (0.3)
(breaths per minute) 40-49 25 (8.4) 32 (10.6)
50-128 272 (91.0) 270 (89.1)
Median (IQR) 64.0 (58.0, 72.0) 63.0 (54.0, 72.0)
Nasal flaring No 54 (18.1) 60 (19.8)
Yes 245 (81.9) 243 (80.2)
Lower chest wall indrawing No 41 (13.7) 46 (15.2)
Yes 258 (86.3) 257 (84.8)
Plasma zinc conc.(µmol/L) Median (IQR) (n = 104) 14.0(7.5, 23.7) (n = 108) 11.3 (7.6, 19.4)
Plasma ferritin conc.(ng/ml) Median (IQR) (n = 108) 90.5(35.5, 165.5) (n = 109) 104.0 (36.0, 198.0)
Soluble transferrin receptor conc. (µg/ml) Median (IQR) (n = 119) 7.4(5.3, 9.5) (n = 115) 6.7 (4.9, 8.6)
Soluble transferrin- receptor-ferritin index  
(sTfR-F index)
Median (IQR) (n = 108) 3.7(2.5, 5.8) (n = 108) 3.3 (2.3, 5.3)
Plasma C-Reactive Protein (mg/L) Median (IQR) (n = 107) 13.5(0.6, 86.1) (n = 107) 19.1 (0.6, 186.0)
IQR – interquartile range
Figure 3. Profile of six months follow up (long term).
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Table 3. Treatment outcomes from six months of either placebo or zinc*
outComes PlaCebo mean (n) ZinC mean (n) DifferenCe (95% Ci)* P-value
Height (cm) 80.87 (92) 79.90 (89) 0.20 (-0.74,1.13) 0.681
HAZ -1.01 (92) -0.80 (89) 0.05 (-0.15,0.25) 0.611
WHZ -0.50 (90) -0.64 (88) -0.20 (-0.46,0.05) 0.121
Growth rate (cm per month) 0.81 (98) 0.87 (100) 0.02 (-0.07,0.11) 0.704
Plasma zinc conc. (µmol/L) 19.92 (86) 22.04 (75) 2.53 (-0.75,5.81) 0.131
Plasma ferritin conc. (ng/ml) 57.79 (86) 26.07 (82) -20.56 (-52.77,11.66) 0.211
Plasma soluble transferrin receptor conc. (µg/ml) 8.78 (88) 8.87 (87) 0.22 (-1.12,1.57) 0.746
Plasma C-Reactive Protein (mg/L) 15.57 (87) 8.44 (81) -6.18 (-16.45,4.09) 0.238
Soluble transferrin-receptor-ferritin index (sTfR-F index) 7.69 (86) 9.02 (82) 1.57 (-0.68,3.83) 0.171
Outcomes Placebo n/N (%) Zinc n/N (%) OR (95% CI) P-value
% with HAZ<-2 17/92 (18.5) 12/89 (13.5) 0.69 (0.31,1.54) 0.361
% with MUAC<12.5 cm 2/93 (2.2) 5/93 (5.4) 2.59 (0.49,13.68) 0.264
% Anergy 84/85 (98.8) 86/87 (98.9) 1.02 (0.06,16.64) 0.987
CI – confidence interval, OR – odds ratio, HAZ – height for age z score, WHZ – weight for height z score, sTfR – soluble transferrin receptor, MUAC 
– mid upper arm circumference
*Adjusted for baseline age, sex, HAZ, WHZ, pneumonia severity and zinc concentration.
Table 2. Treatment outcomes from 7 days of either placebo or zinc
outComes PlaCebo n/n (%) ZinC n/n (%) or (95% Ci)* P-value
Treatment failure:
Day-5 41/293 (14.0) 42/298(14.1) 1.08(0.65,1.80) 0.773
Day-10 15/286 (5.2) 17/290(5.9) 1.18(0.54,2.60) 0.682
Median (IQR) time to resolution (hours) Placebo median (N)† Zinc median (N)† Ratio (95% CI)† P-value
Oxygen saturation <90% 7.2 (42) 5.9 (36) 1.33 (0.82,2.14) 0.251
Lower chest wall indrawing 24.4 (258) 23.0 (257) 0.84 (0.74,0.96) 0.011
Nasal flaring 13.4 (245) 13.2 (243) 0.96 (0.83,1.11) 0.574
Grunting 4.9 (109) 5.3 (81) 1.11 (0.85,1.44) 0.448
Head nodding 4.0 (25) 3.3 (31) 0.71 (0.39,1.31) 0.274
Sternal retraction 18.7 (21) 11.0 (23) 0.51 (0.31,0.82) 0.006
Central cyanosis 1.4 (12) 1.8 (12) 0.60 (0.31,1.15) 0.121
Respiratory rate ≥50 per min 21.0 (272) 17.9 (270) 0.89 (0.76,1.04) 0.142
Respiratory rate ≥40 per min 54.1 (297) 51.4 (302) 1.13 (0.95,1.34) 0.168
All signs of severity‡ 42.3 (36) 30.9 (31) 0.81 (0.58,1.15) 0.242
Discharge 95.9 (292) 94.7 (296) 1.04 (0.94,1.15) 0.468
*Adjusted for baseline age, sex, height for age, weight for age, and weight for height z scores and pneumonia severity.
†Number of participants with the symptom at baseline.
‡Oxygen saturation <90%, lower chest wall indrawing, nasal flaring.
Figure 4. Plasma ferritin and soluble tranferrin 
receptor concentrations, and sTfR-F index at 
baseline and after six months of supplementation.
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DISCUSSION
This study did not show a reduction in treatment failure in children with severe pneumonia who were 
given daily zinc supplementation along with standard antibiotic treatment. There was no overall benefit 
in recovery from all signs of severe pneumonia. There was marginal benefit for time to resolution of LCWI 
and sternal retraction but this was relatively small and in the context of the study’s overall findings was 
of doubtful clinical significance.
Until now, efforts to identify a marker of zinc status have focused predominantly on the response to chang-
es in dietary zinc intake [18]. The distribution of plasma zinc concentrations among a representative sam-
ple of a population has also been recommended to assess the risk of zinc deficiency in that population 
[19]. To our knowledge, this is the first randomised trial of the impact of zinc supplementation on severe 
pneumonia where zinc status has also been assessed within the trial by simultaneously measuring the re-
sponse to zinc supplementation on plasma zinc, growth and immunity. Our population was not zinc de-
ficient, as shown by absence of an impact of zinc supplementation on growth and immune competence, 
and the lack of efficacy of zinc supplementation may be due to an absence of deficiency. Even at baseline 
when plasma zinc concentrations would have been depressed by the high levels of inflammation only 
33% of subjects had concentrations below the referent cut-off of 65 mg/L (9.9 µmol/L) and by the end of 
supplementation only 12% of the placebo and 6% of the zinc arms had low plasma zinc with median 
plasma CRP concentrations of 3.3 and 3.1 mg/L respectively. International Zinc Nutrition Consultative 
Group recommends that if more than 20% of the population has a serum zinc concentration below 
9.9 μmol/L, the whole population should be considered to be at risk of zinc deficiency [20]. This suggests 
that our target population was not zinc deficient, which is also supported by the fact that only a small 
proportion of children were stunted.
In addition to poor dietary zinc intake [9], Gambian children are also at increased risk of zinc deficiency 
because of excessive endogenous loss of zinc due to environmental enteropathy and repeated diarrhoea 
episodes. In spite of these risk factors, our study children were not manifestly zinc deficient, though many 
were under-nourished. Rural African children are generally at risk of dietary zinc deficiency. However, 
the growth response to long term supplementation trials varied widely in trials conducted in Africa. An 
earlier study in Gambia among apparently healthy rural pre-school children did not show an impact of 
long-term zinc supplementation on growth [21]. Similarly, long-term trials of zinc supplementation among 
apparently healthy school children in rural Zimbabwe and in low income suburb in Uganda did not show 
overall growth response [22,23]. In contrast, Umeta et al showed significant effect of zinc supplementa-
tion on linear and ponderal growth in apparently healthy breastfed stunted and non-stunted infants in 
rural Ethiopia [16]. However, a recent meta-analysis that included 50 studies showed a small increase in 
height and weight [24]. In addition to subclinical zinc deficiency, there could be a deficiency of other 
growth limiting type 2 nutrients (as for example dietary protein) [25] in countries like Gambia, Uganda 
or Zimbabwe which were not given with zinc supplementation.
A subclinical zinc deficiency cannot be excluded. It is possible that repletion of zinc in sub-clinically 
zinc-deficient children does not confer benefit in recovery from severe pneumonia. Irrespective of wheth-
er our population was zinc-replete or had a subclinical deficiency the result does not suggest that zinc 
has any important pharmacological impact (ie, beyond the correction of deficiency) on the recovery of 
severe pneumonia in this population.
A majority of studies conducted in resource poor settings in Asia, Africa, and Latin America have not 
shown any benefit of zinc supplementation when used as an adjunct therapy in the management of se-
vere pneumonia [26-29]. Only three studies showed overall benefit of zinc as an adjunct treatment of se-
vere pneumonia [8,30,31]. Srinivasan et al [30] could not show any benefit for time to normalization of 
respiratory rate, temperature and oxygen saturation, although the study showed a significant reduction 
in case-fatality. However, in a stratified analysis, the reduction in mortality was limited to HIV infected 
children. A recent meta-analysis of nine zinc supplementation trials, as an adjunct treatment of severe 
pneumonia, did not show any benefit in time to recovery, length of hospital stay, treatment failure or 
change of antibiotics [32]. It is also possible that the low specificity of the WHO definition of severe pneu-
monia may have contributed to the study’s negative result as a lack of specificity in the diagnostic criteria 
for measuring study outcomes biases the risk/rate ratio towards null values.
General increase in plasma zinc in both arms of our study compared to baseline concentrations was likely 
due to plasma zinc being redistributed to tissues by an acute phase reaction during the episode of severe 
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